CrystalO Biopharma Co., Ltd. announced that it has entered into a collaboration and licensing agreement with Almirall, S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, to jointly develop innovative drug candidates for skin diseases. The deal is worth up to approximately €254.5 million in upfront, milestone and royalty payments.
Retains exclusive development and commercialization rights post‑POC
–
Financial Terms
Component
Direction
Detail
Upfront Payment
Almirall → CrystalO
Paid at deal signing
Milestone Payments
Almirall → CrystalO
Based on R&D, regulatory and commercial successes
Tiered Royalties (Global ex‑Mainland China)
Almirall → CrystalO
On future net sales
Total Potential Value
Almirall → CrystalO
Up to approximately €254.5 million
Tiered Royalties (Mainland China)
CrystalO → Almirall
Based on future product sales in Mainland China
Strategic Rationale & Market Impact
AI‑Driven Discovery Validation: The agreement positions CrystalO’s AI‑ and structural biology‑driven drug discovery platform as a validated engine for first‑class dermatology assets, with a global pharma partner funding discovery through clinical POC.
Dermatology Focus: Almirall’s core positioning in medical dermatology makes this a targeted fit, reinforcing its pipeline replenishment strategy in skin diseases — a therapeutic area with rising global demand.
China Retention: CrystalO retains exclusive Mainland China rights post‑POC, preserving upside in the world’s second‑largest pharmaceutical market while Almirall commercializes globally outside Mainland China.
Two‑Way Royalty Structure: The reciprocal royalty arrangement — Almirall paying tiered royalties on ex‑China sales while CrystalO pays tiered royalties on China sales — aligns both parties’ incentives across the product lifecycle.
Forward‑Looking Statements This brief contains forward‑looking statements regarding the collaboration’s research progress, clinical milestones, and commercial potential. Actual results may differ due to risks including drug discovery outcomes, regulatory approvals, and market dynamics.-Fineline Info & Tech
By Fineline Cube